Using the affective bias test to predict drug-induced negative affect: implications for drug safety

British Journal of Pharmacology

Volumn 174, Issue 19, 2017, Pages 3200-3210

  Stuart, S A ^a   Wood, C M ^a   Robinson, E S J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CORTICOSTERONE; LIPOPOLYSACCHARIDE; MONTELUKAST; RECOMBINANT ALPHA INTERFERON; RETINOIC ACID; TETRABENAZINE; VARENICLINE; ACETIC ACID DERIVATIVE; ALPHA INTERFERON; IMMUNOLOGIC FACTOR; QUINOLINE DERIVATIVE; SUCROSE;

AFFECT; AFFECTIVE BIAS TEST; ANIMAL EXPERIMENT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; LEARNING; MALE; MEMORY; NEGATIVE AFFECT; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; REWARD; SUCROSE PREFERENCE TEST; TASK PERFORMANCE; ANIMAL; DECISION MAKING; PRECLINICAL STUDY; PROCEDURES; SPRAGUE DAWLEY RAT;

ACETATES; AFFECT; ANIMALS; CARBAMAZEPINE; CHOICE BEHAVIOR; CORTICOSTERONE; DRUG EVALUATION, PRECLINICAL; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LEARNING; LIPOPOLYSACCHARIDES; MALE; QUINOLINES; RATS, SPRAGUE-DAWLEY; REWARD; SUCROSE; TETRABENAZINE; VARENICLINE;

EID: 85028569800     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13972     Document Type: Article

References (70)

1. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744–5869.
2. Alexander SPH, Peters JA, Kelly E, Marrion N, Benson HE, Faccenda E et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Ligand-gated ion channels. Br J Pharmacol 172: 5870–5903.
3. Andersohn F, Schade R, Willich SN, Garbe E (2010). Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 75: 335–340.
4. Berlin I, Givry-Steiner L, Lecrubier Y, Puech AJ (1998). Measures of anhedonia and hedonic responses to sucrose in depressive and schizophrenic patients in comparison with healthy subjects. Eur Psychiatry 13: 303–309.
5. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D et al. (2003). Interferon-alpha-induced changes in tryptophan metabolism relationship to depression and paroxetine treatment. Biol Psychiatry 54: 906–914.
6. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R (2002). Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 7: 468–473.
7. Celano CM, Freudenreich O, Fernandez-Robles C, Stern TA, Caro MA, Huffman JC (2011). Depressogenic effects of medications: a review. Dialogues Clin Neurosci 13: 109–125.
8. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
9. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9: 46–56.
10. De La Garza R, Asnis GM, Pedrosa E, Stearns C, Migdal AL, Reinus JF et al. (2005). Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Prog Neuropsychopharmacol Biol Psychiatry 29: 781–792.
11. Deutsch-Feldman M, Picetti R, Seip-Cammack K, Zhou Y, Kreek MJ (2015). Effects of handling and vehicle injections on adrenocorticotropic and corticosterone concentrations in Sprague–Dawley compared with Lewis rats. JAALAS 54: 35–39.
12. Dichter GS, Smoski MJ, Kampov-Polevoy AB, Gallop R, Garbutt JC (2010). Unipolar depression does not moderate responses to the Sweet Taste Test. Depress Anxiety 27: 859–863.
13. Elliott R, Zahn R, Deakin JF, Anderson IM (2011). Affective cognition and its disruption in mood disorders. Neuropsychopharmacology 36: 153–182.
14. Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR et al. (2005). Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 58: 175–189.
15. Evers EA, van der Veen FM, Jolles J, Deutz NE, Schmitt JA (2006). Acute tryptophan depletion improves performance and modulates the BOLD response during a Stroop task in healthy females. Neuroimage 32: 248–255.
16. FDA (2008). Public health advisory: important information on Chantix (varenicline) [online]. Available at: http://www.fda.gov/drugs/drugsafety/publichealthadvisories/ucm051136 (accessed 23/02/2017)
17. FDA (2009). Rimonabant briefing document: Endocrine and metabolic drugs advisory committee meeting. [online] Available at: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fdabackgrounder.pdf (accessed 23/02/2017)
18. Ferguson SA, Cisneros FJ, Gough B, Hanig JP, Berry KJ (2005). Chronic oral treatment with 13-cis-retinoic acid (isotretinoin) or all-trans-retinoic acid does not alter depression-like behaviors in rats. Toxicol Sci 87: 451–459.
19. Forbes NF, Stewart CA, Matthews K, Reid IC (1996). Chronic mild stress and sucrose consumption: validity as a model of depression. Physiol Behav 60: 1481–1484.
20. Giertler C, Bohn I, Hauber W (2003). The rat nucleus accumbens is involved in guiding of instrumental responses by stimuli predicting reward magnitude. Eur J Neurosci 18: 1993–1996.
21. Gregus A, Wintink AJ, Davis AC, Kalynchuk LE (2005). Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats. Behav Brain Res 156: 105–114.
22. Hales CA, Stuart SA, Anderson MH, Robinson ES (2014). Modelling cognitive affective biases in major depressive disorder using rodents. Br J Pharmacol 171: 4524–4538.
23. Harmer CJ, Goodwin GM, Cowen PJ (2009a). Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry 195: 102–108.
24. Harmer CJ, O'Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A et al. (2009b). Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry 166: 1178–1184.
25. Harris RB, Zhou J, Youngblood BD, Smagin GN, Ryan DH (1997). Failure to change exploration or saccharin preference in rats exposed to chronic mild stress. Physiol Behav 63: 91–100.
26. Hinchcliffe JK, Stuart SA, Mendl M, Robinson ESJ (2017). Further validation of the affective bias test for predicting antidepressant and pro-depressant risk: effects of pharmacological and social manipulations in male and female rats. Psychopharmacology (Berl) 22: 1–22.
27. Horder J, Cowen PJ, Di Simplicio M, Browning M, Harmer CJ (2009). Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharmacology (Berl) 205: 85–91.
28. Ihaku D, Cameron L, Suzuki M, Molet S, Martin J, Hamid Q (1999). Montelukast, a leukotriene receptor antagonist, inhibits the late airway response to antigen, airway eosinophilia, and IL-5-expressing cells in Brown Norway rats. J Allergy Clin Immunol 104: 1147–1154.
29. Jankovic J, Beach J (1997). Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48: 358–362.
30. Johnson SA, Fournier NM, Kalynchuk LE (2006). Effect of different doses of corticosterone on depression-like behavior and HPA axis responses to a novel stressor. Behav Brain Res 168: 280–288.
31. Joormann J, Gotlib IH (2006). Is this happiness I see? Biases in the identification of emotional facial expressions in depression and social phobia. J Abnorm Psychol 115: 705–714.
32. Kenney C, Hunter C, Mejia N, Jankovic J (2006). Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol 29: 259–264.
33. Kentner AC, Miguelez M, James JS, Bielajew C (2006). Behavioral and physiological effects of a single injection of rat interferon-alpha on male Sprague-Dawley rats: a long-term evaluation. Brain Res 1095: 96–106.
34. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
35. Kubera M, Curzytek K, Duda W, Leskiewicz M, Basta-Kaim A, Budziszewska B et al. (2013). A new animal model of (chronic) depression induced by repeated and intermittent lipopolysaccharide administration for 4 months. Brain Behav Immun 31: 96–104.
36. Lattal KA, Gleeson S (1990). Response acquisition with delayed reinforcement. J Exp Psychol Anim Behav Process 16: 27–39.
37. Leppänen JM (2006). Emotional information processing in mood disorders: a review of behavioral and neuroimaging findings. Curr Opin Psychiatry 19: 34–39.
38. Lydall ES, Gilmour G, Dwyer DM (2010). Analysis of licking microstructure provides no evidence for a reduction in reward value following acute or sub-chronic phencyclidine administration. Psychopharmacology (Berl) 209: 153–162.
39. Manalai P, Woo JM, Postolache TT (2009). Suicidality and montelukast. Expert Opin Drug Saf 8: 273–282.
40. Mathews A, MacLeod C (2005). Cognitive vulnerability to emotional disorders. Annu Rev Clin Psychol 1: 167–195.
41. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
42. Mula M, Sander J (2007). Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 30: 555–567.
43. Murphy FC, Smith KA, Cowen PJ, Robbins TW, Sahakian BJ (2002). The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. Psychopharmacology (Berl) 163: 42–53.
44. Nunes EJ, Randall PA, Hart EE, Freeland C, Yohn SE, Baqi Y et al. (2013). Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression. J Neurosci 33: 19120–19130.
45. Patten SB, Love EJ (1994). Drug-induced depression. Incidence, avoidance and management. Drug Saf 10: 203–219.
46. Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF et al. (2009). Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 124: 699–706.e698.
47. Pizzagalli DA (2014). Depression, stress, and anhedonia: toward a synthesis and integrated model. Annu Rev Clin Psychol 10: 393–423.
48. Quinn GP, Shore PA, Brodie BB (1959). Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther 127: 103–109.
49. Raison CL, Demetrashvili M, Capuron L, Miller AH (2005). Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19: 105–123.
50. Redrobe JP, Bourin M (1999). Evidence of the activity of lithium on 5-HT1B receptors in the mouse forced swimming test: comparison with carbamazepine and sodium valproate. Psychopharmacology (Berl) 141: 370–377.
51. Refsgaard LK, Haubro K, Pickering DS, Stuart SA, Robinson ES, Andreasen JT (2016). Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test. Psychopharmacology (Berl) 233: 3763–3770.
52. Reid I, Forbes N, Stewart C, Matthews K (1997). Chronic mild stress and depressive disorder: a useful new model? Psychopharmacology (Berl) 134: 365–367 discussion 371-367.
53. Reith DM, Edmonds L (2007). Assessing the role of drugs in suicidal ideation and suicidality. CNS Drugs 21: 463–472.
54. Robinson ES, Roiser JP (2016). Affective biases in humans and animals. Curr Top Behav Neurosci 28: 263–286.
55. Roiser JP, Levy J, Fromm SJ, Goldman D, Hodgkinson CA, Hasler G et al. (2012). Serotonin transporter genotype differentially modulates neural responses to emotional words following tryptophan depletion in patients recovered from depression and healthy volunteers. J Psychopharmacol 26: 1434–1442.
56. Rollema H, Hajós M, Seymour PA, Kozak R, Majchrzak MJ, Guanowsky V et al. (2009). Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol 78: 813–824.
57. Sahin C, Doostdar N, Neill JC (2016). Towards the development of improved tests for negative symptoms of schizophrenia in a validated animal model. Behav Brain Res 312: 93–101.
58. Sherdell L, Waugh CE, Gotlib IH (2012). Anticipatory pleasure predicts motivation for reward in major depression. J Abnorm Psychol 121: 51–60.
59. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH et al. (2016). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44: D1054–D1068.
60. Stuart SA, Butler P, Munafò MR, Nutt DJ, Robinson ES (2013). A translational rodent assay of affective biases in depression and antidepressant therapy. Neuropsychopharmacology 38: 1625–1635.
61. Stuart SA, Robinson ES (2015). Reducing the stress of drug administration: implications for the 3Rs. Sci Rep 5: 14288.
62. Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell D (2015). Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ 350: h1109.
63. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP et al. (2003). The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138: 544–553.
64. van der Veen FM, Evers EA, Deutz NE, Schmitt JA (2007). Effects of acute tryptophan depletion on mood and facial emotion perception related brain activation and performance in healthy women with and without a family history of depression. Neuropsychopharmacology 32: 216–224.
65. Vogel JR, Mikulka PJ, Spear NE (1968). Effects of shifts in sucrose and saccharine concentrations on licking behavior in the rat. J Comp Physiol Psychol 66: 661–666.
66. Wallace-Boone TL, Newton AE, Wright RN, Lodge NJ, McElroy JF (2008). Behavioral and pharmacological validation of the gerbil forced-swim test: effects of neurokinin-1 receptor antagonists. Neuropsychopharmacology 33: 1919–1928.
67. Willner P, Muscat R, Papp M (1992). Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev 16: 525–534.
68. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R (1987). Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 93: 358–364.
69. Yirmiya R (1996). Endotoxin produces a depressive-like episode in rats. Brain Res 711: 163–174.
70. Zheng G, Dwoskin LP, Crooks PA (2006). Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J 8: E682–E692.